Compare DexCom, Inc. (DXCM) vs iShares MSCI Germany (DAX) (EWG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares MSCI Germany (DAX) — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while iShares MSCI Germany (DAX) trades at $40.96 (market cap $1.42B). The key difference: DexCom, Inc. is far larger — about 22.4× iShares MSCI Germany (DAX)'s market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares MSCI Germany (DAX) for 54 Days on average.
| DXCM | EWG | |
|---|---|---|
Market Cap | $31.86B | $1.42B |
Volume | 3,607,070 | 1,110,573 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $44.59 |
52-Week Low | $54.84 | $38.08 |
Typical Hold Time | 62 Days | 54 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
EWG trades at $40.96 with minimal daily movement (+0.12%). Technical indicators show a bearish trend with strong selling pressure across moving averages and oscillators, though RSI levels suggest potential oversold conditions. The stock faces resistance at $41 with support at $40. Recent European market news highlights mixed sentiment with resilient equities but concerns about ECB rate hikes and energy-driven inflation pressures.
The outlook remains cautious due to bearish technicals and macroeconomic headwinds from potential ECB tightening. Investment opportunity exists if oversold RSI levels trigger a rebound, but risks include further rate hikes and energy price volatility. Stock performance hinges on European economic stability and inflation control.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →
